|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
Why disrupted body clocks trigger liver cancer [The Economist]
|
|
|
|
|
|
Dr
Fu and Dr Moore knew from their previous research that disrupting the
circadian rhythms of mice causes the rodents’ livers to overproduce this
substance. They also knew that liver cancer commonly appears in mice
engineered to lack certain genes required for the management of
day-night cycles.
|
|
|
|
|
|
|
2.10 Etiologie - Alcool
|
|
|
|
3.1 Tabac
|
|
|
On the pleasure of smoking [The Conversation]
|
|
|
|
|
|
The
argument that smoking and inhaling nicotine is “pleasurable” is a bit
like saying being beaten up every day is something you want to continue
with, because hey, it feels so good when the beating stops for a while.
|
|
|
|
|
|
|
|
3.7 Alcool
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
Niraparib Maintenance Therapy in Ovarian Cancer [Now@NEJM]
|
|
|
|
|
|
A
randomized, placebo-controlled, phase 3 trial conducted by Mirza et al.
evaluated the efficacy and safety of niraparib versus placebo as
maintenance treatment in a broad population of patients with
platinum-sensitive, recurrent ovarian cancer.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
Cancer drugs may remain approved despite lack of benefit [Reuters]
|
|
|
|
|
|
"In
following the principle of 'first, do no harm,' the FDA should promptly
withdraw approval for cancer drugs that are proven to have no clinical
benefit," JAMA Internal Medicine editors Drs. Scott Bauer and Rita
Redberg write in a note accompanying the new study.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.9.4 ENA
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
21st Century Cures Act will distort the meaning of ‘FDA approved’ [STAT]
|
|
|
|
|
|
The
most recent version of the 21st Century Cures Act has a new addition:
prompting the FDA to approve new regenerative therapies based on
clinical anecdotes and surrogate endpoints like shrinkage of a tumor
instead of clinically relevant outcomes like longer survival or improved
quality of life.
|
|
|
|
|
|
|
|
|
|
6.11 Patients
|
|
|